Medivir to present at the Redeye Growth Day
Medivir AB announced its upcoming presentation at the Redeye Growth Day on June 2, 2021, which will be accessible via live broadcast. The presentation will later be available on Medivir's website. Medivir focuses on developing innovative drugs for cancer treatment, including MIV-818, a pro-drug targeting liver cancer cells. The company emphasizes partnerships in its drug development, notably with IGM Biosciences for the treatment of solid tumors. Medivir's share is listed on the Nasdaq Stockholm Small Cap list under the ticker MVIR.
- None.
- None.
STOCKHLOM, June 1, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the virtual meeting Redeye Growth Day on June 2, 2021.
The presentation is live broadcasted and can be followed at:
https://www.redeye.se/events/808637/redeye-growth-day-2021
The presentation will be available after the meeting on Medivirs website; www.medivir.com.For additional information, please contact
Magnus Christensen, interim CEO and CFOTelephone: +46 8 5468 3100E-mail: magnus.christensen@medivir.com
Medivir in brief
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of MIV-818, a pro-drug designed to selectively treat liver cancer cells and to minimize side effects.
Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/medivir/r/medivir-to-present-at-the-redeye-growth-day,c3358116
The following files are available for download:
Press release (PDF) |
View original content:http://www.prnewswire.com/news-releases/medivir-to-present-at-the-redeye-growth-day-301302618.html
SOURCE Medivir
FAQ
When will Medivir present at the Redeye Growth Day?
Where can I watch Medivir's presentation?
What is Medivir's focus in drug development?
What drug is Medivir developing for liver cancer?
Which ticker symbol is associated with Medivir's stock?
